Effect of Cilnidipine on plasma aldosterone: influence of autonomic function

Effect of Cilnidipine on plasma aldosterone: influence of autonomic function - Cilnidipine suppression of aldosterone and autonomic function

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011088

Enrollment

Registered

2013-07-02

Start date

2013-07-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertensive patients

Interventions

Cilnidipine 5-20mg/day

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients who were assessed autonomic nervous function 2) Patients with essential hypertension 3) Patients who take Ca channel blocker, except for Cilnidipine 4) Patients who agreed to participate with written informed consent

Exclusion criteria

Exclusion criteria: 1) Patients with age of 20 years or less 2) Patients with contraindication to Cilnidipine 3) Patients who are judged to be inappropriate to participate by the physicians

Design outcomes

Primary

Measure	Time frame
Changes in plasma renin activity and aldosterone concentration	—

Secondary

Measure	Time frame
Changes in value of the following data (Blood Pressure, cardiac mass, IMT, PWV and urinary albumin creatinine ratio)	—

Countries

Japan

Contacts

Public ContactKurajoh, Masafumi

Hyogo college of medicine Division of Endocrinology and Metabolism, Department of Internal Medicine

mkurajoh@gmail.com0798-45-6472

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026